Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus

American Journal of Physiology - Endocrinology and Metabolism

Volumn 282, Issue 5 45-5, 2002, Pages

  Christ, Emanuel R ^a   Carroll, Paul V ^b   Albany, Elaine ^b   Margot Umpleby, A ^b   Lumb, Peter J ^b   Wierzbicki, Anthony S ^b   Sönksen, Peter H ^b   Russell Jones, David L ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Growth hormone secretion; Insulin like growth factor I; Stable isotope technique; Type 1 diabetes mellitus; Very low density lipoprotein apolipoprotein B turnover study

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; FATTY ACID; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SOMATOMEDIN C; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; GROWTH HORMONE RELEASE; HUMAN; IMMUNORADIOMETRIC ASSAY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036084535     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00470.2001     Document Type: Article

References (47)

1. Randomised placebo-controlled trial of human recombinant insulin-like growth factor-I plus intensive insulin therapy in adolescents with insulin dependent diabetes mellitus
2. Effect of diabetes and its control on insulin-like growth factors in the young subject with type 1 diabetes
3. Growth hormone and hepatic lipoprotein metabolism
4. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus
5. Insulin regulates insulin-like growth factor-I mRNA in rat hepatocytes
6. Members of Growth Hormone Research Society Scientific Committee. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review
7. IGF-I treatment in adults with type 1 diabetes. Effects on glucose and protein metabolism in the fasting state and during a hyperinsulinaemic-euglycaemic amino acid clamp
8. Recombinant human insulin-like growth factor-1 therapy in adults with type 1 diabetes mellitus: Effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment
9. RhIGF-I administration reduces insulin requirement, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM
10. The effects of recombinant insulin-like growth factor-I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin-dependent) diabetes mellitus
11. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: A stable isotope study
12. Tracer-to-tracee ratio for analysis of stable isotope tracer data: Link with radioactive kinetic formalism
13. Comparison of immunoturbimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma
14. Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in NIDDM
15. Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in heterozygous familial hypercholesterolaemia: A stable isotope study
16. Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus
17. Plasma lipid and lipoprotein disorders in IDDM
18. Growth factors and diabetic complications
19. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the ultracentrifuge
20. Assembly and secretion of hepatic very low-density lipoprotein
21. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) correlates with increased cardiovascular risk in non-insulin dependent diabetes
22. Blood volume
23. Insulin therapy and GH-IGF-I axis disorders in diabetes: Impact of glycaemic control and hepatic insulinisation
24. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
25. Insulin-like growth factor-I stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans
26. Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects
27. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1) and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus
28. Serum total IGF-I, free IGF-I and IGFBP-1 levels in an elderly population: Relation to cardiovascular risk factors and disease
29. Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease
30. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in non-insulin dependent diabetes mellitus
31. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin dependent diabetes mellitus
32. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to angiographic progression
33. 13]leucine infusion in man: A method for measuring human intracellular leucine tracer enrichment
34. Apolipoprotein E phenotyping from serum Western blotting
35. Impact of human growth hormone on plasma lipoprotein concentrations
36. Lipoprotein heterogeneity and apolipoprotein B metabolism
37. Apolipoprotein B signal peptide and apolipoprotein E genotype as determinants of the hepatic secretion of VLDL apoB in obese men
38. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
39. Importance of growth hormone for the induction of hepatic low density lipoprotein receptor
40. Substrate delivery as a determinant of hepatic apoB secretion
41. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus
42. Inappropriately elevated plasma insulin-like growth factor II in relation to suppressed insulin-like growth factor I in the diagnosis of non-islet cell tumor hypoglycaemia
43. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor-I in insulin-dependent diabetes mellitus: Effects on the growth hormone/IGF/IGF-binding protein system
44. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro
45. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels and insulin secretion
46. Insulin-like growth factor-I improves glucose and lipid metabolism in type II diabetes mellitus